76
We need your help for some crucial #LongCOVID research! If you live in the New York area, have FULLY recovered from COVID-19 infection and it has been AT LEAST 12 weeks since you were first sick, please email us at prcovid@mountsinai.org @PutrinoLab
RT highly appreciated 🙏🏼
77
So truly honored to be named a @Yale Sterling Professor 🙏🏼
medicine.yale.edu/news-article/i…
78
“COVID toes” are swollen discolored toes (and fingers) that were seen in areas with high incidence of COVID-19, but the cause is unknown. This new study by @JeffGehlhausen et al shows lack of association between covid toes and SARS-CoV-2 infection. 🧵(1/)
pnas.org/content/119/9/…
79
What immune cell features are most predictive of COVID outcomes?
@mkuchroo @JcsHuang Patrick Wong et al used ML algorithm Multiscale PHATE to assign each immune cell type in COVID patients a mortality-likelihood score. Latest from @KrishnaswamyLab 💪🏼 (1/)
go.nature.com/3K0QCqi
80
Check out our latest review on the immunology and immunopathology of COVID-19 (both acute and #longCOVID). So fortunate to work with brilliant #womeninSTEM on this review - my #shero friends @MiriamMerad @blish_lab @sallustolab 💪🏼
science.org/doi/10.1126/sc…
81
This new preprint by Stadler et al. integrated data from 37 randomized controlled trials to ask how the timing and dose of passive antibodies (monoclonal Ab & convalescent plasma) predict protection from SARS-CoV-2 disease. A short 🧵 (1/)
medrxiv.org/content/10.110…
82
Very important work by @PGTimmune and colleagues showing that repeated SARS-CoV-2 antigen exposure (infection and/or vaccines) does not lead to an exhausted T cell phenotype.
#GetBoosted
nature.com/articles/s4159… twitter.com/PGTimmune/stat…
83
An excellent piece on why we should be looking to nasal spray as the future of COVID booster vaccines by @Carolynyjohnson
@NIAIDNews please include our Prime and Spike in the upcoming vaccine bake-off 🥺
washingtonpost.com/health/2022/04…
84
A Phase 2 clinical trial of oral camostat mesylate during early phase of COVID-19 in outpatients reduced illness course (including fatigue) and prevented loss of smell and taste!
Work of fantastic colleagues at @YaleMed. (1/)
medrxiv.org/content/10.110…
85
Thank you @ASlavitt for speaking up about #longCOVID 🙏🏼 We need a lot more public attention, research, therapy and drugs to combat this debilitating disease. We also need similar attention/resources/research/treatment for #MECFS that results after infection with other pathogens. twitter.com/ASlavitt/statu…
86
So excited to launch the new Center for Infection & Immunity @YaleCII at @YaleMed!! This center will investigate fundamental mechanisms of infection and immunity that hold key to better prevention, diagnosis and treatment of wide range of diseases. (1/)
medicine.yale.edu/cii/
87
Q: Why can nasal vaccines do?
A:“Nasal sprays assemble a separate set of antibodies known as immunoglobulin A (IgA). These populate the spongy mucosal tissues of the nose, mouth and throat, where the COVID-causing coronavirus first lands." #PrimeandSpike
By @mvbroadfoot twitter.com/sciam/status/1…
88
CD8 T cells help fight off viral infection by detecting and killing infected cells. CD8 T cells detect MHC I + viral peptide on infected cells. One of the common tricks viruses use to avoid killing is to inhibit MHC I expression and presentation. (2/)
pubmed.ncbi.nlm.nih.gov/19498380/
89
In this study, @MiyuMoriyama et al investigate how well SARS-CoV-2 variants of concern (VOC) suppress MHC I needed for recognition by cytotoxic T cells. This question is important to understand how well the virus limits CD8 killing 🧵(1/) @biorxivpreprint
biorxiv.org/content/10.110…
90
In conclusion, VOCs do not evolve to further escape from CD8 T beyond the ancestral SARS-CoV-2 virus. The virus uses multiple pathways to inhibit MHC I. If one is missing, others compensate. Given this, CD8 T cell-based therapeutic approaches may be difficult for COVID-19. (End)
91
I’m so grateful that @japanairlinesJP requires masking in the airplane and at airports 🙏🏼
Taking off to Tokyo to celebrate the winners of the Maria Sklodowska-Curie Prize for young female scientists 👩🏻🔬
92
It’s time to invest in next generation COVID vaccines that not only prevent severe disease but also block infection and transmission. It makes sense to induce mucosal immunity to fight a mucosal viral infection. My opinion in @nytimes today👇🏽
nytimes.com/2022/05/16/opi…
93
Please read our latest review by @jan_choutka et al. on “Unexplained post-acute infection syndromes”.
What a privilege to work with Jan Choutka, who is an #MECFS patient, expert and advocate. Grateful to @mhornig on her expertise/insights 🙏🏼 (1/)
nature.com/articles/s4159…
94
With millions of #longCOVID patients, it is becoming better known that even a mild infection can lead to longterm debilitating health problems. SARS-CoV-2 joins the long list of other pathogens that cause post-acute infection syndrome (PAIS). (2/)
95
What could be the possible causes of PAIS? Similar to #longCOVID, we hypothesize a) pathogen reservoir/remnants, b) autoimmunity, c) dysbiosis of microbiome/virome, and d) unrepaired tissue damage. None are mutually exclusive. (6/)
96
An important study by @zalaly and colleagues of >13 million people shows that vaccines (prior to infection) only reduce #longCOVID risk by 15% with the largest risk reduction in blood clots and pulmonary sequelae but less protection of other organ systems. Please wear a mask! twitter.com/zalaly/status/…
97
@mocoband @fitterhappierAJ @DrEricDing @EricTopol @DrPatSoonShiong @farid__jalali @dgurdasani1 @jeremyfaust @ToshiAkima @RadCentrism @LeonardiBot @EnemyInAState Thank you @mocoband for sharing. This report adds to a growing evidence of viral persistence in the GI tract, possibly aided by virus shutting down MHC I and evading T cell killing.
biorxiv.org/content/10.110…
98
A brilliant & timely review by Prof. #DianeEGriffin on the persistence of viral RNA following RNA virus infection - which can be associated with late progressive disease or nonspecific lingering symptoms of post-acute infection syndromes (#PAIS). (1/)
dx.plos.org/10.1371/journa…
99
First question addressed is WHERE viral RNA can persist. After a variety of RNA virus infection, viral RNA can persist not only in immune privileged sites (brain, eyes, and testes), but also in blood, lymphoid tissue, joints, respiratory tract, GI tissues, and kidney. (2/)
100
Consequences of persistent viral RNA may include organ-specific as well as nonspecific postviral syndromes such as long COVID, post-Ebola, and post-polio syndromes, characterized by symptoms including fatigue, headache, muscle pain, and joint pain. (3/)
We study innate and adaptive immunity against viruses and study disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII